SEC Form 4 · accession 0001179110-19-000357
IMMUNOGEN INC · IMGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark J Enyedy
Officer — Chief Executive Officer · Director
Period of report
Jan 3, 2019
Accepted (ET)
Jan 4, 2019 · 11:09 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000855654
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 3, 2019 | A | 2,455 | $4.08 | A | 534,838 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from July 1, 2018 through December 31, 2018.
- F2In accordance with the ESPP; these shares were purchased based on 85% of the closing price of the issuer's common stock on December 31, 2018.